Profile picture

Associate Professor Michel Zeitouni

Pitie Salpetriere APHP University Hospital, Paris (France)
Membership: ESC Professional Member
Follow
Logo ESC

Contributor content

Heart rate and cardiovascular outcomes with and without beta-blocker in post-mi patients: a pre-specified analysis of the ABYSS trial.
Presentation
Heart rate and cardiovascular outcomes with and without beta-blocker in post-mi patients: a pre-specified analysis of the ABYSS trial.
Read more
Hydroceramide as a novel Biomarker of Premature Atherosclerosis
Presentation
Hydroceramide as a novel Biomarker of Premature Atherosclerosis
Read more
Intra venous antithrombotic in acute myocardial infarction complicated with cardiogenic shock
Presentation
Intra venous antithrombotic in acute myocardial infarction complicated with cardiogenic shock
Read more
Pre-treatment with P2Y12 inhibitors in acute myocardial infarction with cardiogenic shock
Presentation
Pre-treatment with P2Y12 inhibitors in acute myocardial infarction with cardiogenic shock
Read more
Levosimendan in patients with cardiogenic shock refractory to dobutamine weaning
Presentation
Levosimendan in patients with cardiogenic shock refractory to dobutamine weaning
Read more
Early versus delayed introduction of renin angiotensin aldosterone system inhibitors in cardiogenic shock
Presentation
Early versus delayed introduction of renin angiotensin aldosterone system inhibitors in cardiogenic shock
Read more
Have the ESC guidelines improved the identification and prevention of individuals at risk of premature myocardial infarction?
Presentation
Have the ESC guidelines improved the identification and prevention of individuals at risk of premature myocardial infarction?
Read more
Causes and predictors of short, intermediate and long-term mortality in patients after PCI
Presentation
Causes and predictors of short, intermediate and long-term mortality in patients after PCI
Read more
Apixaban 2.5 mg twice daily is effective and safe for patients with atrial fibrillation and combinations of advanced age, low body weight, and elevated creatinine: insights from ARISTOTLE
Presentation
Apixaban 2.5 mg twice daily is effective and safe for patients with atrial fibrillation and combinations of advanced age, low body weight, and elevated creatinine: insights from ARISTOTLE
Read more
Investigator versus Core Lab evaluation of coronary blood flow in PCI of patients in cardiogenic shock: a substudy of the CULPRIT-SHOCK trial.
Presentation
Investigator versus Core Lab evaluation of coronary blood flow in PCI of patients in cardiogenic shock: a substudy of the CULPRIT-SHOCK trial.
Read more

ESC 365 is supported by

novartis Explore sponsored resources